Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Abstract Background As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated w...

全面介紹

書目詳細資料

Principais autores:	Phil McEwan, Samantha Webster, Thomas Ward, Michael Brenner, Anupama Kalsekar, Yong Yuan
格式:	Artigo
語言:	Inglês
出版:	BMC 2017-07-01
叢編:	Cost Effectiveness and Resource Allocation
主題:	Hepatitis C virus Daclatasvir Cost-effectiveness Sofosbuvir
在線閱讀:	http://link.springer.com/article/10.1186/s12962-017-0077-4
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!